Michael Hofman
@DrMHofman
Followers
6K
Following
3K
Media
518
Statuses
2K
Working together to improve patient outcomes with personalised medicine & precision oncology: theranostics. PET/CT, prostate cancer ☢️ Prof 🇦🇺
Melbourne, Victoria
Joined December 2013
Terbium-161 vs lutetium-177: Comparing next-gen radioligands for #ProstateCancer. @DrMHofman @PeterMacCC joins Oliver Sartor, MD @EJHospital to discuss the #VIOLET study evaluating Terbium-161 PSMA therapy in #mCRPC. #WatchNow > https://t.co/xG6uE2HGW6
0
4
11
Congrats to @DrScottTagawa on his presentation of PSMA-Addition, and to @AzadOncology on a very thoughtful discussion. Compelling data data but agree with Azad’s take that questions remain. Excellent points around the possibility of a “sink effect” & risks of secondary
0
13
45
We're running a BOGO on $5K challenge accounts TODAY! Post your proof of purchase below and like this post, we'll choose a Player Profit community member to receive an ADDITIONAL $5K CHALLENGE ACCOUNT!
10
5
35
Early stable or rising PSA does not preclude subsequent biochemical or pain response with additional cycles of ¹⁷⁷Lu-PSMA-617 treatment. https://t.co/BB8XwwegAf
#NuclearMedicine #ProstateCancer #RPTherapy @davcmed @DrMHofman @AzadOncology
0
7
17
Breaking news podcast - And in ADDITION…. LuPSMA added to doublet improves rPFS in mHSPC. Detailed discussion with @DrScottTagawa @DrMHofman @declangmurphy with comments from @AzadOncology #esmo25 #prostatecancer
1
6
13
🎯Patient individualisation is a Must! For Patient selection and follow up! The aim is that the Patient live longer BUT also BETTER 🥇 #qualityoflife #PSMAddition #ESMO25 #prostatacancer @DrScottTagawa
1
9
16
0
5
60
The AlphaBet trial @PeterMacCC @TheLancetOncol release today @myESMO #ESMO25: combining Lu-177 PSMA-I&T + Ra-223 in men with metastatic castration-resistant #ProstateCancer is safe, feasible, and active. ✅ No dose-limiting toxicities 💪 PSA-50% decline in 55% 🧬 Supports future
6
52
114
🌞 @FocusMeeting is open! Our presidents : ELENA CASTRO 🇪🇸& Karim BENSALAH 🇫🇷 @piet_ost : amazing talk and new formula proposal for pelvic lymph nodes radiotherapy, patients selection : @Roach + @DrMHofman = @VedangMurthy 💯 Thoughts?
2
10
39
🚀 Is 6 cycles of Lutetium-177 PSMA the limit? Definitely not! 💪 Our research in 50+ men with prostate cancer treated beyond 6 cycles shows that re-treatment can further improve outcomes. 📉 PSA ↓ >50% in 40% of patients on re-treatment. 🕒 Median overall survival: an
3
41
120
Let’s Unite to Fight Cancer! 💪 Ten years ago, we made history with Australia’s first-ever Lutetium-PSMA treatment - research that’s changed prostate cancer care worldwide. Since then, our team has led 10+ clinical trials, bringing cutting-edge science straight to patients and
unitetofightcancer.org
UNITE with hundreds of walkers and riders for a life-saving 10-day challenge. This October, the choice is yours. Walk or ride to raise vital funds for cancer research.
0
12
39
🚀 Is 6 cycles of Lutetium-177 PSMA the limit? Definitely not! 💪 Our research in 50+ men with prostate cancer treated beyond 6 cycles shows that re-treatment can further improve outcomes. 📉 PSA ↓ >50% in 40% of patients on re-treatment. 🕒 Median overall survival: an
3
41
120
Let’s Unite to Fight Cancer! 💪 Ten years ago, we made history with Australia’s first-ever Lutetium-PSMA treatment - research that’s changed prostate cancer care worldwide. Since then, our team has led 10+ clinical trials, bringing cutting-edge science straight to patients and
unitetofightcancer.org
UNITE with hundreds of walkers and riders for a life-saving 10-day challenge. This October, the choice is yours. Walk or ride to raise vital funds for cancer research.
0
12
39
📢 JAMA Oncol (Oct 2, 2025): Phase 2 RCT: PSMA PET–guided intensification of salvage RT post-prostatectomy shows improved biochemical control vs standard RT. ➡️ Suggests molecular imaging can personalize salvage therapy. 👉10.1001/jamaoncol.2025.3625 @JAMAOnc @ONCOassist
1
72
153
#eanm25 Maximizing PSMA Theranostics? Grace Kong from @PeterMacCC with a fantastic journey of Australian on going trials. Combinations with ARPIs, chemo, inmuno, radiotherapy, alpha and many more!! @DrMHofman @urotoday @pros_tic @dandanmena @sepsis000 @julired3
0
2
18
Shaping the future of Lu-177 PSMA-617 radiopharmaceutical therapy in prostate cancer: is earlier better, or is patient selection key? https://t.co/QvrCzMs6r8
@AzadOncology @Annals_Oncology #PSMAfore
3
24
77
🔥 LUNAR trial: In oligometastatic hormone-sensitive #ProstateCancer, adding 2 cycles of 177Lu-PSMA 💥 ☢️ before SBRT ⬆️ doubled PFS (18 vs 7 mo, HR 0.32, p<0.001) with minimal added adverse events. 🚀 PSMA-RLT + SBRT = new frontier #ASTRO25 #RadOnc #NuclearMedicine @ASTRO_org
9
90
200
Augerlicious Webinar online @pros_tic TV: https://t.co/07Spbp0gh1 Terbium-161 Double Punch to Cancer Cells @PCF_Science @declangmurphy @RenuEapen
1
6
26
We’re seeking a Senior Research Administration Officer to support the @pros_tic Director and Program Manager in their vital work. This is a fast-paced and varied role where no two days are the same. Apply here: https://t.co/X5zfN3w8GU
careers.petermac.org
Administration Officer- Cancer Imaging/ProsTIC
0
2
7
Registrations now open! https://t.co/fFA9hGVRMf Following the outstanding success of the 2024 Preceptorship, which welcomed over 360 delegates from 26 countries and featured expert speakers from five continents, we are excited to invite you to our ProsTIC Preceptorship 2026.
0
3
9